SAR247799 + Placebo + Sildenafil + Acetylcholine
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Microvascular Coronary Artery Disease
Conditions
Microvascular Coronary Artery Disease
Trial Timeline
Mar 7, 2018 → Dec 22, 2018
NCT ID
NCT03462017About SAR247799 + Placebo + Sildenafil + Acetylcholine
SAR247799 + Placebo + Sildenafil + Acetylcholine is a phase 1 stage product being developed by Sanofi for Microvascular Coronary Artery Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03462017. Target conditions include Microvascular Coronary Artery Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03462017 | Phase 1 | Completed |
Competing Products
7 competing products in Microvascular Coronary Artery Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zibotentan + Placebo oral tablet | AstraZeneca | Phase 2 | 52 |
| Lercanidipine + Valsartan + Nicorandil + Doxazosin + Moxonidin + Pindolol + Amiloride, hydrochlorothiazide | Novartis | Pre-clinical | 23 |
| Ranolazine + Placebo | Gilead Sciences | Approved | 84 |
| Ranolazine + Placebo | Gilead Sciences | Phase 2 | 51 |
| Temanogrel + Placebo | Pfizer | Phase 2 | 51 |
| SAR407899 + Placebo + Adenosine + Regadenoson + 13N-ammonia + 82Rubidium | Sanofi | Phase 2 | 51 |
| Felzartamab + Placebo | Biogen | Phase 2 | 49 |